The Experts below are selected from a list of 51288 Experts worldwide ranked by ideXlab platform
Emmanuel Nowak - One of the best experts on this subject based on the ideXlab platform.
-
rationale and design of the canari study a case control study investigating the association between prostate cancer and 5 alpha reductase Inhibitors for symptomatic benign prostate hypertrophy by linking sniiram and pathology laboratories in a specif
Fundamental & Clinical Pharmacology, 2018Co-Authors: Luciemarie Scailteux, Frederic Balusson, Sebastien Vincendeau, Nathalie Riouxleclercq, Emmanuel NowakAbstract:Benign prostate hypertrophy (BPH) could be associated with low urinary symptoms requiring medical treatment: 5 alpha-reductase Inhibitors (5-ARI) or ɑ-blockers. Two clinical trials investigating 5-ARI use in prostate cancer (PCa) primary prevention highlighted a potential safety signal with an increased risk of high grade PCa. Later observational studies failed to show similar results but have some limits. The present paper focuses on describing the protocol of the CANARI study and its feasibility, as regards the matching process of two pseudo-anonymous databases. The study concerned patients living in the Brittany region (France) between 2010 and 2013. We designed a case-control study nested within a cohort of men treated by medical drugs licensed for symptomatic BPH between 2010 and 2011. Cases were patients with incident PCa diagnosed between 2012 and 2013 identified through French Health database (SNIIRAM). Gleason score was searched through Brittany pathology laboratories. Controls were patients without PCa diagnosis. Local pathology laboratories database was constituted in Brittany, gathering Gleason scores. No unique identification number is available in France; linkage of SNIIRAM and Brittany pathology laboratories database was made by deterministic matching. We matched 859 cases to Gleason grading (119 had Gleason score ≥ 8 and 740 had Gleason < 8); around 22% of cases received 5-ARI and 78% α-blockers or phytotherapy. The CANARI study investigated in a population of men treated for BPH the risk of PCa with 5-ARI, according to Gleason grade thanks to SNIIRAM database enriched by local pathological results. This article is protected by copyright. All rights reserved.
-
Rationale and design of the CANARI study: a case-control study investigating the association between prostate cancer and 5-Alpha-Reductase Inhibitors for symptomatic benign prostate hypertrophy by linking SNIIRAM and pathology laboratories in a speci
Fundamental and Clinical Pharmacology, 2018Co-Authors: Luciemarie Scailteux, Frederic Balusson, Sebastien Vincendeau, Nathalie Rioux-leclercq, Emmanuel NowakAbstract:Benign prostate hypertrophy (BPH) could be associated with low urinary symptoms requiring medical treatment: 5-Alpha-Reductase Inhibitors (5-ARI) or alpha-blockers. Two clinical trials investigating 5-ARI use in prostate cancer (PCa) primary prevention highlighted a potential safety signal with an increased risk of high-grade PCa. Later observational studies failed to show similar results but have some limits. This paper focuses on describing the protocol of the CANARI study and its feasibility, as regards the matching process of two pseudo-anonymous databases. The study concerned patients living in the Brittany region (France) between 2010 and 2013. We designed a case-control study nested within a cohort of men treated by medical drugs licensed for symptomatic BPH between 2010 and 2011. Cases were patients with incident PCa diagnosed between 2012 and 2013 identified through French Health database (SNIIRAM). Gleason score was searched through Brittany pathology laboratories. Controls were patients without PCa diagnosis. Local pathology laboratories database was constituted in Brittany, gathering Gleason scores. No unique identification number is available in France; linkage of SNIIRAM and Brittany pathology laboratories database was made by deterministic matching. We matched 859 cases to Gleason grading (119 had Gleason score = 8 and 740 had Gleason < 8); around 22% of cases received 5-ARI and 78% alpha-blockers or phytotherapy. The CANARI study investigated in a population of men treated for BPH the risk of PCa with 5-ARI, according to Gleason grade thanks to SNIIRAM database enriched by local pathological results.
Ferdinando Fusco - One of the best experts on this subject based on the ideXlab platform.
-
alpha 1 adrenergic antagonists 5 alpha reductase Inhibitors phosphodiesterase type 5 Inhibitors and phytotherapic compounds in men with lower urinary tract symptoms suggestive of benign prostatic obstruction a systematic review and meta analysis of u
Neurourology and Urodynamics, 2018Co-Authors: Ferdinando Fusco, Cosimo De Nunzio, Massimiliano Creta, Mauro Gacci, Vincenzo Li Marzi, Enrico Finazzi AgroAbstract:AIMS: To perform a systematic review and meta-analysis of studies evaluating the urodynamic outcomes of alpha-1 adrenergic antagonists (ABs), 5-alpha reductase Inhibitors (5-ARIs), phosphodiesterase type 5 Inhibitors (PDE5is), and phytotherapic compounds in patients with lower urinary tract symptoms related to benign prostatic obstruction (LUTS/BPO). METHODS: A systematic review of PubMed/Medline, ISI Web of Knowledge, and Scopus databases was performed in June 2017. We included full papers that met the following criteria: original research; English language; human studies; enrolling LUTS/BPO patients; reporting maximum urinary flow (Qmax), and detrusor pressure at maximum urinary flow (PdetQmax). The primary endpoint was variation in bladder outlet obstruction index (BOOI). Secondary endpoints were variations in Qmax and PdetQmax. RESULTS: Twenty-three studies involving 1044 patients were included in the final analysis. Eighteen, three, two, and one study evaluated the urodynamic outcomes of ABs, 5-ARIs, PDE5is, and phytotherapic compounds, respectively. BOOI, PdetQmax, and Qmax improved in a statistically significant manner in patients receiving ABs and in those receiving 5-ARIs. The overall pooled data showed a mean BOOI change of -15.40 (P < 0.00001) and of -10.55 (P = 0,004) for ABs and 5-ARIs, respectively. Mean PdetQmax and Qmax changes were:12.30 cm H2 O (P < 0.00001) and +2.27 ml/s (P < 0.00001) for ABs and -9.63 cm H2 O (P = 0.05), and +1.18 mL/s (P = 0.04) for 5-ARIs. PDE5is and phytotherapic compounds had no significant effects on urodynamic parameters. CONCLUSIONS: ABs and 5-ARIs efficiently improve BOOI in men with LUTS/BPO. Both treatments are associated with a clinically significant decrease in PdetQmax but only marginal improvements in Qmax.
-
Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-Alpha-Reductase inhibitor consumers different?
World journal of urology, 2014Co-Authors: Ferdinando Fusco, Massimiliano Creta, Davide Arcaniolo, Gaetano Piccinocchi, Giovanni Arpino, Matteo Laringe, Roberto Piccinocchi, Nicola Longo, Paolo Verze, Francesco MangiapiaAbstract:Purpose We aimed to describe, in a daily clinical practice setting, the demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS), to compare the characteristics of patients receiving 5-Alpha-Reductase Inhibitors (5-ARIs) with those not receiving them and to investigate predictors of 5-ARI prescription.
Aria F. Olumi - One of the best experts on this subject based on the ideXlab platform.
-
High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia.
The Journal of urology, 2020Co-Authors: Hu Zhang, Daniel M. Frendl, Zongwei Wang, Aria F. OlumiAbstract:Purpose:Although clinical trials demonstrate 5-alpha reductase Inhibitors are efficacious treatments for benign prostatic hyperplasia, they have low reported medication adherence outside of clinica...
-
5 alpha reductase Inhibitors 5 ari and prostate cancer mortality among men with regular access to screening and health care
Journal of Clinical Oncology, 2020Co-Authors: Lorelei A Mucci, Aria F. Olumi, Claire H Pernar, Emily Rencsok, Konrad H Stopsack, Sydney Grob, Edward Giovannucci, Adam S Kibel, Mark A Preston, Kathryn M WilsonAbstract:39Background: The excess risk of high-grade prostate cancer in the Prostate Cancer Prevention Trial (PCPT) among men randomized to finasteride raised concerns that a chemoprevention benefit would b...
-
PD33-03 HIGH REAL-WORLD MEDICATION ADHERENCE AND DURABLE CLINICAL BENEFIT IN MEDICARE PATIENTS PRESCRIBED 5 ALPHA-REDUCTASE Inhibitors FOR BENIGN PROSTATIC HYPERPLASIA RELATED LOWER URINARY TRACT SYMPTOMS
The Journal of Urology, 2020Co-Authors: Daniel M. Frendl, Hu Zhang, Zongwei Wang, Aria F. OlumiAbstract:INTRODUCTION AND OBJECTIVE:Although clinical trials have demonstrated 5 alpha-reductase Inhibitors (5ARIs) are efficacious treatments for benign prostatic hyperplasia (BPH), 5ARIs have low reported...
Luciemarie Scailteux - One of the best experts on this subject based on the ideXlab platform.
-
rationale and design of the canari study a case control study investigating the association between prostate cancer and 5 alpha reductase Inhibitors for symptomatic benign prostate hypertrophy by linking sniiram and pathology laboratories in a specif
Fundamental & Clinical Pharmacology, 2018Co-Authors: Luciemarie Scailteux, Frederic Balusson, Sebastien Vincendeau, Nathalie Riouxleclercq, Emmanuel NowakAbstract:Benign prostate hypertrophy (BPH) could be associated with low urinary symptoms requiring medical treatment: 5 alpha-reductase Inhibitors (5-ARI) or ɑ-blockers. Two clinical trials investigating 5-ARI use in prostate cancer (PCa) primary prevention highlighted a potential safety signal with an increased risk of high grade PCa. Later observational studies failed to show similar results but have some limits. The present paper focuses on describing the protocol of the CANARI study and its feasibility, as regards the matching process of two pseudo-anonymous databases. The study concerned patients living in the Brittany region (France) between 2010 and 2013. We designed a case-control study nested within a cohort of men treated by medical drugs licensed for symptomatic BPH between 2010 and 2011. Cases were patients with incident PCa diagnosed between 2012 and 2013 identified through French Health database (SNIIRAM). Gleason score was searched through Brittany pathology laboratories. Controls were patients without PCa diagnosis. Local pathology laboratories database was constituted in Brittany, gathering Gleason scores. No unique identification number is available in France; linkage of SNIIRAM and Brittany pathology laboratories database was made by deterministic matching. We matched 859 cases to Gleason grading (119 had Gleason score ≥ 8 and 740 had Gleason < 8); around 22% of cases received 5-ARI and 78% α-blockers or phytotherapy. The CANARI study investigated in a population of men treated for BPH the risk of PCa with 5-ARI, according to Gleason grade thanks to SNIIRAM database enriched by local pathological results. This article is protected by copyright. All rights reserved.
-
Rationale and design of the CANARI study: a case-control study investigating the association between prostate cancer and 5-Alpha-Reductase Inhibitors for symptomatic benign prostate hypertrophy by linking SNIIRAM and pathology laboratories in a speci
Fundamental and Clinical Pharmacology, 2018Co-Authors: Luciemarie Scailteux, Frederic Balusson, Sebastien Vincendeau, Nathalie Rioux-leclercq, Emmanuel NowakAbstract:Benign prostate hypertrophy (BPH) could be associated with low urinary symptoms requiring medical treatment: 5-Alpha-Reductase Inhibitors (5-ARI) or alpha-blockers. Two clinical trials investigating 5-ARI use in prostate cancer (PCa) primary prevention highlighted a potential safety signal with an increased risk of high-grade PCa. Later observational studies failed to show similar results but have some limits. This paper focuses on describing the protocol of the CANARI study and its feasibility, as regards the matching process of two pseudo-anonymous databases. The study concerned patients living in the Brittany region (France) between 2010 and 2013. We designed a case-control study nested within a cohort of men treated by medical drugs licensed for symptomatic BPH between 2010 and 2011. Cases were patients with incident PCa diagnosed between 2012 and 2013 identified through French Health database (SNIIRAM). Gleason score was searched through Brittany pathology laboratories. Controls were patients without PCa diagnosis. Local pathology laboratories database was constituted in Brittany, gathering Gleason scores. No unique identification number is available in France; linkage of SNIIRAM and Brittany pathology laboratories database was made by deterministic matching. We matched 859 cases to Gleason grading (119 had Gleason score = 8 and 740 had Gleason < 8); around 22% of cases received 5-ARI and 78% alpha-blockers or phytotherapy. The CANARI study investigated in a population of men treated for BPH the risk of PCa with 5-ARI, according to Gleason grade thanks to SNIIRAM database enriched by local pathological results.
Francesco Mangiapia - One of the best experts on this subject based on the ideXlab platform.
-
Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-Alpha-Reductase inhibitor consumers different?
World journal of urology, 2014Co-Authors: Ferdinando Fusco, Massimiliano Creta, Davide Arcaniolo, Gaetano Piccinocchi, Giovanni Arpino, Matteo Laringe, Roberto Piccinocchi, Nicola Longo, Paolo Verze, Francesco MangiapiaAbstract:Purpose We aimed to describe, in a daily clinical practice setting, the demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS), to compare the characteristics of patients receiving 5-Alpha-Reductase Inhibitors (5-ARIs) with those not receiving them and to investigate predictors of 5-ARI prescription.
